Last reviewed · How we verify
Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
This fixed-dose combination reduces blood pressure and cardiovascular risk through calcium channel blockade, angiotensin II receptor antagonism, potassium-sparing diuresis, and cholesterol lowering.
This fixed-dose combination reduces blood pressure and cardiovascular risk through calcium channel blockade, angiotensin II receptor antagonism, potassium-sparing diuresis, and cholesterol lowering. Used for Hypertension with dyslipidemia, Cardiovascular risk reduction in hypertensive patients.
At a glance
| Generic name | Amlodipine, Telmisartan, Amiloride Compound , Simvastatin |
|---|---|
| Also known as | CHIEF |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Drug class | Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin) |
| Target | L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine blocks L-type calcium channels to relax vascular smooth muscle; telmisartan blocks AT1 angiotensin II receptors to reduce vasoconstriction and aldosterone secretion; amiloride inhibits epithelial sodium channels to promote sodium and water excretion while retaining potassium; simvastatin inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis. Together these agents provide synergistic antihypertensive and cardioprotective effects.
Approved indications
- Hypertension with dyslipidemia
- Cardiovascular risk reduction in hypertensive patients
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Hyperkalemia
- Muscle pain or myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: